Drugs / PF-03463275
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01159626 | Jul → Nov 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00567203 | Nov 2007 → May 2008 | schizophrenia | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01911676 | Aug 2013 → Dec 2018 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00977522 | Nov 2009 → Sep 2010 | schizophrenia | Pfizer | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-03463275 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01911676 ↗ |
| Known as | PF-3463275 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00567203 ↗ |
| Action | Inhibit | “Glycine transporter 1 inhibitor” CHEMBL563251 ↗ |
| Modality | Small molecule | — CHEMBL563251 ↗ |
| Route | Oral | “PF-03463275 oral controlled release formulation” NCT01159626 ↗ |
| Target | SLC6A9 | “Glycine transporter 1 inhibitor” CHEMBL563251 ↗ |